Dolores Redondo‐Pachón
A5071002542- Renal Transplantation Outcomes and Treatments
- Organ Transplantation Techniques and Outcomes
- Organ Donation and Transplantation
- Transplantation: Methods and Outcomes
- Renal Diseases and Glomerulopathies
- Renal and Vascular Pathologies
- COVID-19 Clinical Research Studies
- Dialysis and Renal Disease Management
- Cytomegalovirus and herpesvirus research
- Long-Term Effects of COVID-19
- Complement system in diseases
- Pregnancy and Medication Impact
- Neurological Complications and Syndromes
- Immune Cell Function and Interaction
- Frailty in Older Adults
- Blood groups and transfusion
- COVID-19 Impact on Reproduction
- Nutrition and Health in Aging
- Systemic Lupus Erythematosus Research
- Systemic Sclerosis and Related Diseases
- Organ and Tissue Transplantation Research
- Muscle and Compartmental Disorders
- Chronic Kidney Disease and Diabetes
- Reproductive System and Pregnancy
- Advanced biosensing and bioanalysis techniques
Hospital Del Mar
2016-2025
Hospital del Mar Research Institute
2015-2024
Parc de Salut
2017-2024
Universitat Pompeu Fabra
2024
Municipal Institute for Medical Research
2013-2022
Universitat Autònoma de Barcelona
2016-2019
Instituto de Salud Carlos III
2016-2018
Hospital General Universitario de Elche
2011-2014
Hospital Universitario Reina Sofía
2010
Abstract Background. Patients on kidney replacement therapy comprise a vulnerable population and may be at increased risk of death from coronavirus disease 2019 (COVID-19). Currently, only limited data are available outcomes in this patient population. Methods. We set up the ERACODA (European Renal Association COVID-19 Database) database, which is specifically designed to prospectively collect detailed transplant dialysis patients with COVID-19. For analysis, were included who presented...
Kidney transplant recipients may be at a high risk of developing critical coronavirus disease 2019 (COVID-19) illness due to chronic immunosuppression and comorbidities. We identified hospitalized adult kidney 12 centers in the United States, Italy, Spain who tested positive for COVID-19. Clinical presentation, laboratory values, immunosuppression, treatment strategies were reviewed, predictors poor clinical outcomes determined through multivariable analyses. Among 9845 across centers, 144...
There are no approved treatments for chronic antibody mediated rejection (ABMR). We conducted a multicenter, prospective, randomized, placebo-controlled, double-blind clinical trial to evaluate efficacy and safety of intravenous immunoglobulins (IVIG) combined with rituximab (RTX) (EudraCT 2010-023746-67). Patients transplant glomerulopathy anti-HLA donor-specific antibodies (DSA) were eligible. estimated glomerular filtration rate (eGFR) <20 mL/min per 1.73m2 and/or severe interstitial...
Acute respiratory distress syndrome associated with coronavirus infection is related to a cytokine storm large interleukin-6 (IL-6) release. The IL-6-receptor blocker tocilizumab may control the aberrant host immune response in patients disease 2019 (COVID-19) . In this pandemic, kidney transplant (KT) recipients are high-risk population for severe and showed poor outcomes. We present multicenter cohort study of 80 KT COVID-19 treated during hospital admission. High mortality rate was...
Coronavirus disease 2019 (COVID-19) has exposed haemodialysis (HD) patients and kidney transplant (KT) recipients to an unprecedented life-threatening infectious disease, raising concerns about replacement therapy (KRT) strategy during the pandemic. This study investigated association of type KRT with COVID-19 severity, adjusting for differences in individual characteristics.
The SARS-Cov-2 infection disease (COVID-19) pandemic has posed at risk the kidney transplant (KT) population, particularly elderly recipients. From March 12 until April 4, 2020, we diagnosed COVID-19 in 16 of our 324 KT patients aged ≥65 years old (4.9%). Many them had contact with healthcare facilities month prior to infection. Median time symptom onset admission was 7 days. All presented fever and all but one pneumonia. Up 33% showed renal graft dysfunction. At diagnosis, mTOR inhibitors...
Studies are urgently needed to characterize immunogenicity, efficacy, and safety of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) mRNA vaccines in kidney transplant (KT) recipients, excluded from major clinical trials. Complex ELISPOT other cellular response techniques have been applied, but simpler tools needed. An easy-to-use real-world monitoring SARS-CoV-2 IgG antibodies against the Spike protein QuantiFERON® IFNγ release assay (IGRA) were performed at baseline 28 days...
Correlation between antibody-mediated rejection (ABMR) and circulating HLA donor-specific antibodies (HLA-DSA) is strong but imperfect in kidney transplant (KT) recipients, raising the possibility of undetected HLA-DSA or non-HLA contributing to ABMR. Detailed evaluation degree matching together with identification KT may help decipher antibody involved.
Antiviral prophylaxis is recommended in cytomegalovirus (CMV)-seropositive kidney transplant (KT) recipients receiving antithymocyte globulin (ATG) as induction. An alternative strategy of premature discontinuation after CMV-specific cell-mediated immunity (CMV-CMI) recovery (immunoguided prevention) has not been studied. Our aim was to determine whether it effective and safe discontinue when CMV-CMI detected continue with preemptive therapy.In this open-label, noninferiority clinical trial,...
Isolated microvascular inflammation (iMVI) without HLA donor-specific antibodies or C4d deposition in peritubular capillaries remains an enigmatic phenotype that cannot be categorized as antibody-mediated rejection (ABMR) recent Banff classifications. We included 221 kidney transplant recipients with biopsies ABMR (n = 73), iMVI 32), and normal 116) diagnoses. compared peripheral blood leukocyte distribution by flow cytometry inflammatory infiltrates among groups. Flow showed fewer...
Abstract CMV infection in kidney transplant recipients (KTRs) has been associated with an increased risk for graft loss and reduced host survival. promotes persistent expansions of NK cells expressing the CD94/NKG2C receptor. The NKG2C (KLRC2) gene is frequently deleted, copy number influences adaptive response NKG2C+ cells. distribution genotypes (NKG2C+/+, NKG2C+/del, NKG2Cdel/del) were studied cross-sectional (n = 253) prospective 122) KTR cohorts. Assessment viremia was restricted to...
Detection of posttransplant donor-specific anti-HLA antibodies (DSA) constitutes a risk factor for kidney allograft loss. Together with complement activation, NK-cell antibody-dependent cell mediated cytotoxicity (ADCC) has been proposed to contribute the microvascular damage associated humoral rejection. In present observational exploratory study, we have tried find relationship circulating and non (DSA HLA non-DSA) peripheral blood subsets clinical features in 393 renal recipients....
Bone mineral density (BMD) measured by dual-energy x-ray absorptiometry is used to assess bone health in kidney transplant recipients (KTR). Trabecular score and vivo microindentation are novel techniques that directly measure trabecular microarchitecture mechanical properties of at a tissue level independently predict fracture risk. We tested the status long-term KTR using all 3 techniques.Cross-sectional study including 40 with more than 10 years follow-up 94 healthy nontransplanted...
Frailty is associated with poorer outcomes among patients waiting for kidney transplantation (KT). Several different tools to measure frailty have been used; however, their predictive value unknown. This a prospective longitudinal study of 449 KT candidates evaluated by the Physical Phenotype (PFP) and FRAIL scale. During period, 296 received KT, while 153 remained listed. Patients who did not get receive transplant were more frequently frail according PFP (16.3 vs. 7.4%, p = 0.013). Robust...
Renal involvement is an unusual but significant Behcet´s disease (BD) complication and AA amyloidosis appears to be the most common etiology. IL-6 a pro-inflammatory cytokine with important role in development. Tocilizumab (TCZ) humanized anti-IL-6 receptor antibody that has emerged as effective specific treatment secondary chronic inflammatory disorders. We report on patient diagnosed BD who developed nephrotic syndrome caused by renal excellent response TCZ therapy.